** Shares of medical equipment maker Revvity fall ~1.6% to $119.05 premarket
** The company expects annual revenue between $2.75 bln and $2.77 bln, down from its previous forecast of $2.77 bln to $2.79 bln
** Q3 revenue from RVTY's Life Sciences segment was $301 mln, missing analysts' expectation of $306.15 mln - data compiled by LSEG
** It reports Q3 adjusted profit of $1.28/share vs analysts' average estimate of $1.13/share
** Favorable margins and lower tax rate enabled the profit beat - TD Cowen analysts
** Up to last close, stock up 10.7% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。